Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Paul M Camic, Mary Pat Sullivan, Emma Harding, Martha Gould, Lawrence Wilson, Sam Rossi-Harries, Adetola Grillo, Roberta McKee-Jackson, Susan M Cox, Joshua Stott, Emilie V Brotherhood, Gill Windle, Sebastian J Crutch
This study investigated co-constructed research poetry as a way to understand the lived experiences of people affected by rarer dementia and as a means to use poetry to convey those experiences to healthcare professionals. Using mixed methods, 71 people living with rarer dementia and care-partners (stakeholders) contributed to co-constructing 27 poems with professional poets; stakeholders' verbatim words were analysed with descriptive qualitative analysis. Stakeholders were also surveyed and interviewed about their participation...
February 17, 2024: Healthcare (Basel, Switzerland)
#22
JOURNAL ARTICLE
Patricio Millar Vernetti, Lucy Norcliffe-Kaufmann, Jose-Alberto Palma, Italo Biaggioni, Cyndya A Shibao, Amanda Peltier, Roy Freeman, Christopher Gibbons, David S Goldstein, Phillip A Low, Wolfgang Singer, Elizabeth A Coon, Mitchell G Miglis, Gregor K Wenning, Alessandra Fanciulli, Steven Vernino, Rebecca A Betensky, Horacio Kaufmann
We aimed to describe the clinical features of patients with pure autonomic failure (PAF) preceding phenoconversion that could be useful as predictive markers for advancing α-synuclein-associated neurodegeneration of the brain. Patients diagnosed with PAF were evaluated at 8 Centers (7-US based and 1 European) and enrolled in a longitudinal observational cohort study (NCT01799915). Subjects underwent detailed assessments of motor, sleep, olfactory, cognitive, and autonomic function and were followed prospectively to determine whether they developed parkinsonism or dementia for up to 10 years...
February 15, 2024: Brain
#23
JOURNAL ARTICLE
Rui He, Jalal Al-Tamimi, Gonzalo Sánchez-Benavides, Guillermo Montaña-Valverde, Juan Domingo Gispert, Oriol Grau-Rivera, Marc Suárez-Calvet, Carolina Minguillon, Karine Fauria, Arcadi Navarro, Wolfram Hinzen
Abnormal deposition of Aβ amyloid is an early neuropathological marker of Alzheimer's disease (AD), arising long ahead of clinical symptoms. Non-invasive measures of associated early neurofunctional changes, together with easily accessible behavioral readouts of these changes, could be of great clinical benefit. We pursued this aim by investigating large-scale cortical gradients of functional connectivity with functional MRI, which capture the hierarchical integration of cortical functions, together with acoustic-prosodic features from spontaneous speech, in cognitively unimpaired older adults with and without Aβ positivity (total N = 188)...
February 14, 2024: Brain Research
#24
JOURNAL ARTICLE
Eshaan J Daas, Coleman S Cowart, Amanda Balmages, Ryan Roten
INTRODUCTION: Acute aortic syndrome (AAS) includes the disease processes of aortic dissection, penetrating atherosclerotic ulcer, and intramural hematoma. This case demonstrates an atypical presentation of the disease and offers approaches to potentially prevent missed diagnoses. CASE REPORT: An 87-year-old female with hypertension and Alzheimer's dementia presented to the emergency department with stable vital signs and a chief complaint of throat pain. Initial work-up was significant for ischemia on electrocardiogram and elevated troponin...
November 2023: Clinical Practice and Cases in Emergency Medicine
#25
JOURNAL ARTICLE
Deepti Putcha, Ana Eustace, Nicole Carvalho, Bonnie Wong, Megan Quimby, Bradford C Dickerson
INTRODUCTION: Visual naming ability reflects semantic memory retrieval and is a hallmark deficit of Alzheimer's disease (AD). Naming impairment is most prominently observed in the late-onset amnestic and logopenic variant Primary Progressive Aphasia (lvPPA) syndromes. However, little is known about how other patients across the atypical AD syndromic spectrum perform on tests of auditory naming, particularly those with primary visuospatial deficits (Posterior Cortical Atrophy; PCA) and early onset (EOAD) syndromes...
2024: Frontiers in Neuroscience
#26
JOURNAL ARTICLE
Ana Carreras Mascaro, Martyna M Grochowska, Valerie Boumeester, Natasja F J Dits, Ece Naz Bilgiҫ, Guido J Breedveld, Leonie Vergouw, Frank Jan de Jong, Martin E van Royen, Vincenzo Bonifati, Wim Mandemakers
Autosomal dominant variants in LRP10 have been identified in patients with Lewy body diseases (LBDs), including Parkinson's disease (PD), Parkinson's disease-dementia (PDD), and dementia with Lewy bodies (DLB). Nevertheless, there is little mechanistic insight into the role of LRP10 in disease pathogenesis. In the brains of control individuals, LRP10 is typically expressed in non-neuronal cells like astrocytes and neurovasculature, but in idiopathic and genetic cases of PD, PDD, and DLB, it is also present in α-synuclein-positive neuronal Lewy bodies...
February 5, 2024: Cellular and Molecular Life Sciences: CMLS
#27
JOURNAL ARTICLE
Friederike A Arlt, Ramona Miske, Marie-Luise Machule, Peter Broegger Christensen, Swantje Mindorf, Bianca Teegen, Kathrin Borowski, Maria Buthut, Rosa Rößling, Elisa Sanchez-Sendin, Scott van Hoof, César Cordero-Gómez, Isabel Bünger, Helena Radbruch, Andrea Kraft, Ilya Ayzenberg, Jaqueline Klausewitz, Niels Hansen, Charles Timäus, Peter Körtvelyessy, Thomas Postert, Kirsten Baur-Seack, Constanze Rost, Robert Brunkhorst, Kathrin Doppler, Niklas Haigis, Gerhard Hamann, Albrecht Kunze, Alexandra Stützer, Matthias Maschke, Nico Melzer, Felix Rosenow, Kai Siebenbrodt, Christian Stenør, Martin Dichgans, Marios K Georgakis, Rong Fang, Gabor C Petzold, Michael Görtler, Inga Zerr, Silke Wunderlich, Ivan Mihaljevic, Paul Turko, Marianne Schmidt Ettrup, Emilie Buchholz, Helle Foverskov Rasmussen, Mahoor Nasouti, Ivan Talucci, Hans M Maric, Stefan H Heinemann, Matthias Endres, Lars Komorowski, Harald Prüss
BACKGROUND: Autoantibodies against the potassium voltage-gated channel subfamily A member 2 (KCNA2) have been described in a few cases of neuropsychiatric disorders, but their diagnostic and pathophysiological role is currently unknown, imposing challenges to medical practice. DESIGN / METHODS: We retrospectively collected comprehensive clinical and paraclinical data of 35 patients with KCNA2 IgG autoantibodies detected in cell-based and tissue-based assays. Patients' sera and cerebrospinal fluid (CSF) were used for characterization of the antigen, clinical-serological correlations, and determination of IgG subclasses...
February 1, 2024: Brain, Behavior, and Immunity
#28
JOURNAL ARTICLE
Brenda L Plassman, Cassie B Ford, Valerie A Smith, Nicole DePasquale, James R Burke, Laura Korthauer, Brian R Ott, Emmanuelle Belanger, Megan E Shepherd-Banigan, Elyse Couch, Eric Jutkowitz, Emily C O'Brien, Corinna Sorenson, Terrie T Wetle, Courtney H Van Houtven
BACKGROUND: Elevated amyloid-β (Aβ) on positron emission tomography (PET) scan is used to aid diagnosis of Alzheimer's disease (AD), but many prior studies have focused on patients with a typical AD phenotype such as amnestic mild cognitive impairment (MCI). Little is known about whether elevated Aβ on PET scan predicts rate of cognitive and functional decline among those with MCI or dementia that is clinically less typical of early AD, thus leading to etiologic uncertainty...
2024: Journal of Alzheimer's Disease: JAD
#29
JOURNAL ARTICLE
Amanda Pasqualotto, Vinícius da Silva, Felipe Mateus Pellenz, Artur Francisco Schumacher Schuh, Ida Vanessa Doederlein Schwartz, Marina Siebert
Atypical parkinsonism (AP) is a group of complex neurodegenerative disorders with marked clinical and pathophysiological heterogeneity. The use of systems biology tools may contribute to the characterization of hub-bottleneck genes, and the identification of its biological pathways to broaden the understanding of the bases of these disorders. A systematic search was performed on the DisGeNET database, which integrates data from expert curated repositories, GWAS catalogues, animal models and the scientific literature...
February 2, 2024: Metabolic Brain Disease
#30
Cristina Villa, Elisa Pellencin, Aurora Romeo, Giorgio Giaccone, Giacomina Rossi, Sara Prioni, Paola Caroppo
BACKGROUND: Microtubule-associated protein tau ( MAPT ) mutations are one of the main causes of genetic Frontotemporal dementia (FTD) and are characterised by high clinical heterogeneity. A behavioural variant of FTD is the principal phenotype, but other rarer phenotypes are described, mostly reported as single cases. In this review, we provide an overview of the clinical phenotypes associated with MAPT mutations in order to define their characteristics and explore genotype-phenotype correlations...
January 16, 2024: Frontiers in Bioscience (Landmark Edition)
#31
JOURNAL ARTICLE
Stephanie L Rayner, Alison Hogan, Jennilee M Davidson, Tyler Chapman, Flora Cheng, Luan Luu, Sharlynn Wu, Selina Zhang, Shu Yang, Ian Blair, Marco Morsch, Roger Chung, Albert Lee
Previously, we demonstrated that the SCFcyclin F complex directly mediates the poly-ubiquitylation of TDP-43, raising the question of whether cyclin F can be used to enhance the turnover of TDP-43. A hurdle to the use of cyclin F, however, is that the overexpression of cyclin F can lead to the initiation of cell death pathways. Accordingly, the aim of this study was to identify and evaluate a less toxic variant of cyclin F. To do so, we first confirmed and validated our previous findings that cyclin F binds to TDP-43 in an atypical manner...
March 2024: Neurobiology of Disease
#32
JOURNAL ARTICLE
Lalani Carlton Jones, Jan Hoffmann, Saamir Mohideen, Biba Stanton, Cristina Bleil, Tom Britton, Peter J Goadsby, Bassel Zebian
CSF-venous fistulas (CVFs) are increasingly recognised as a cause of spontaneous intracranial hypotension. They may present atypically including with brain sagging pseudo-dementia. Cervical CVFs are rare and their management can be difficult due to associated eloquent nerve roots. We report the case of a 49-year-old woman who presented with cognitive decline progressing to coma. Brain imaging showed features of spontaneous intracranial hypotension and a right C7 CVF was identified at digital subtraction and CT myelography...
January 26, 2024: Acta Neurochirurgica
#33
REVIEW
Izaviany Schmitz, Amanda da Silva, Larissa Daniele Bobermin, Carlos-Alberto Gonçalves, Johann Steiner, André Quincozes-Santos
Antipsychotics are commonly prescribed to treat several neuropsychiatric disorders, including schizophrenia, mania in bipolar disorder, autism spectrum disorder, delirium, and organic or secondary psychosis, for example, in dementias such as Alzheimer's disease. There is evidence that typical antipsychotics such as haloperidol are more effective in reducing positive symptoms than negative symptoms and/or cognitive deficits. In contrast, atypical antipsychotic agents have gained popularity over typical antipsychotics, due to fewer extrapyramidal side effects and their theoretical efficacy in controlling both positive and negative symptoms...
November 2023: Experimental Biology and Medicine
#34
JOURNAL ARTICLE
Li-Yun Ma, Ya-Nan Ou, Pei-Yang Gao, Yan Fu, Dan-Dan Zhang, Liu Yang, Jian-Feng Feng, Wei Cheng, Lan Tan, Jin-Tai Yu
BACKGROUND: Antipsychotics (APs) are among the most widely prescribed medications, and have been shown to cause cognitive decline. But previous studies on their effects on dementia risk are controversial and scarce. We aimed to examine the relationships of APs exposure with the risk of dementia. METHODS: Data were obtained from a prospective cohort of 415,100 UK Biobank (UKB) participants. We investigated the effects of APs exposure and their various classes on dementia risk by using multivariable Cox proportional hazard models and further the dose-response effects of oral APs...
January 8, 2024: Journal of Affective Disorders
#35
JOURNAL ARTICLE
Eliza Polyak
Frontotemporal dementia is a neurodegenerative disease characterized by atrophy of the frontal and temporal lobes of the brain, and it is believed to primarily develop based on genetic factors. Its initial symptoms can appear relatively early, even between the ages of 40-50, affecting approximately 15-22 individuals out of 100,000 annually. The disease manifests in various forms, categorized into behavioral, aphasic, and motor variants due to its diverse presentations. The behavioral variant, constituting about half of the cases, is the most common type...
December 2023: Neuropsychopharmacologia Hungarica
#36
Farea Ahmed, Muskan Asim Taimuri, Areeba Ikram, Anusha Sumbal, Sajjad Ali, Mahfuza Anan
Significant atypical neurologic signs have also been recorded in COVID-19 individuals, along with a variety of other extra-pulmonary indications. The COVID-19 virus is neuro-invasive and holds significant potential to produce some unconventional neurologic manifestations.
January 2024: Clinical Case Reports
#37
JOURNAL ARTICLE
Fuga Habuchi, Natsuko Ishida, Ryo Matsushita, Junko Ishizaki, Yukio Suga
BACKGROUND: Patients with dementia are prescribed low-dose atypical antipsychotics (AAPs) to treat psycho-behavioral symptoms. Although AAPs are known to cause diabetes mellitus-related adverse events (DMAEs), information regarding AAPs-induced DMAEs experienced by patients with dementia is lacking. OBJECTIVE: To use the Japan Adverse Drug Event Report (JADER) database to assess the onset tendencies and patterns of DMAEs attributable to AAPs prescribed to patients with dementia...
November 24, 2023: Annals of Pharmacotherapy
#38
JOURNAL ARTICLE
Krithika Rajagopalan, Nazia Rashid, Dilesh Doshi
Aim: Risk of long-term care (LTC) admission (LTCA) associated with atypical antipsychotic (AAP) use among patients with Parkinson's disease psychosis (PDP) is a major concern. However, no comparative studies have examined the differences in risk of LTC admissions between pimavanserin (PIM), the only FDA-approved AAP for PDP, and other off-label AAPs including quetiapine (QUE). Objective: To examine all-cause LTCA rates and risk among PDP patients treated with AAPs such as QUE or PIM. Methods: Analysis of Parts A, B and D claims (100% Medicare sample; 2013-2019) of Medicare beneficiaries with PDP that initiate ≥12-month continuous PIM or QUE monotherapy from 1 January 2014 to 31 December 2018 (i...
January 2024: Journal of Comparative Effectiveness Research
#39
EDITORIAL
Ram J Bishnoi
No abstract text is available yet for this article.
2023: Frontiers in Psychiatry
#40
JOURNAL ARTICLE
Arenn F Carlos, Hiroaki Sekiya, Shunsuke Koga, Rodolfo G Gatto, Monica Castanedes Casey, Nha Trang Thu Pham, Irene Sintini, Mary M Machulda, Clifford R Jack, Val J Lowe, Jennifer L Whitwell, Leonard Petrucelli, R Ross Reichard, Ronald C Petersen, Dennis W Dickson, Keith A Josephs
Transactive response DNA-binding protein 43 (TDP-43) pathology is categorized as type A-E in frontotemporal lobar degeneration and as type α-β in Alzheimer disease (AD) based on inclusion type. We screened amygdala slides of 131 cases with varying ages at death, clinical/neuroimaging findings, and AD neuropathologic changes for TDP-43 pathology using anti-phospho-TDP-43 antibodies. Seven cases (5%) only showed atypical TDP-43 inclusions that could not be typed. Immunohistochemistry and immunofluorescence assessed the atypical star-shaped TDP-43 pathology including its distribution, species, cellular localization, and colocalization with tau...
December 12, 2023: Journal of Neuropathology and Experimental Neurology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
